Label change of liraglutide demonstrates superiority compared to sitagliptin Full Text
Drug Topics, 04/17/2012
FDA approved an update to the product label of liraglutide [rDNA] injection (Victoza, Novo Nordisk), which includes data demonstrating superior blood sugar control and weight reduction when compared with sitagliptin (Januvia, Merck), according to a press release from Novo Nordisk.



